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41.001
Detecting Carbapenemase Producers in the Clinic
C. Giske
Karolinska University, Stockholm, Sweden
Carbapenem resistance among Klebsiella pneumoniae, is
increasing in many parts of the world, and the treatment
options for such strains are very limited. The mechanisms
are mainly transferable carbapenemases of K. pneumoniae
carbapenemase (KPC) or metallo-betalactamase (MBL) type
(mainly VIM), but also OXA-48 carbapenemases, as well as
extendedspectrum beta-lactamases or AmpC in combination
with porin loss. Infection control is of crucial importance for
combating such resistance, and depends on adequate detec-
tion of carbapenemase-producing isolates. Several authors
have reported on problems of detecting such isolates, and
the reasons and possible solutions are discussed.
Carbapenem-producers have carbapenem MICs below the
current clinical breakpoints of EUCAST and CLSI. However,
EUCASTs epidemiological cut-offs (ECOFFs) values, the limit
of the wild-type populations, have been found useful to
identify such carbapenemase-producers. Disk diffusion cor-
relates to the current MIC ECOFFs are under development,
and seem to be working equally well with the tentative
zone ECOFFs. In particular meropenem and ertapenem pro-
duce a good separation between wild-type isolates and
carbapenem-producers. Automated antimicrobial suscepti-
bility testing (AST) systems will in most cases detect all
carbapenemaseproducers when using ECOFFs actively when
reading the quantitative AST results.
Phenotypic tests for conﬁrmation of carbapenemase-
production comprise the modiﬁed Hodge test (MHT), and
in-house combination disks containing carbapenems in com-
bination with boronic acid (for KPC detection) or zinc
chelators (for MBL-detection). The MHT has high sensitiv-
ity for detection of KPC, but lower for MBL. Also, there are
problems with speciﬁcity, mainly with AmpC hyperproduc-
ers. The combination diskmethod has recently been updated
with the addition of cloxacillin as a third inhibitor, in order to
separate AmpC hyperproduction plus porin loss (synergy with
cloxacillin and boronic acid) from KPC (synergy with boronic
acid only). Further, dipicolinic acid has better speciﬁcity for
MBL-detection than EDTA.
Although the above mentioned recommendations seem
to identify carbapenemase-producers among K. pneumo-
niae, it is still uncertain whether they will be adequate
for detection of carbapenemases in other species of Enter-
obacteriaceae. Further, there are still concerns regarding
detection with automated AST-systems. Detection depends
on the carbapenems included in the test.
doi:10.1016/j.ijid.2010.02.1882
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1.002
linical Impact and Current Epidemiology of Carbapene-
ase producers
. Thomson
Creighton Unviversity School of Medicine, Omaha, NE, USA
Carbapenemase-producing pathogens have become a
ajor and increasing infectious disease threat. Their most
erious impact is the lack effective therapies for the infec-
ions they cause. Given that laboratory detection is often
oor, our understanding of their epidemiology is incom-
lete. Some types of carbapenemase producers are already
biquitous. For other types, there are known hotspots of
ccurrence. KPC producers are mostly detected in the
astern USA and Israel, but have also been detected in
ome European and Asian countries. Metallo-- lactamase
MBL) producers mostly occur in Asia, Europe, Australia
nd South America. OXAcarbapenemase have been detected
orldwide. The most rapidly spreading pathogens are
robably Acinetobacter baumannii that produce OXA car-
apenemases and KPC-producing Klebsiella pneumoniae.
owever, these enzymes also occur in species that are
ess closely monitored, e.g. OXA-producing Enterobacteri-
ceae and KPC-producing A. baumannii and P. aeruginosa.
here appears to be less rapid spread of Enterobacteriaceae,
seudomonas aeruginosa and Acinetobacter that produce
ransmissible MBLs, but this observation may be a reﬂection
f suboptimal laboratory testing rather than reality. Prompt
nd accurate laboratory detection is critical. Outbreaks
nd therapeutic failures have resulted from testing prob-
ems. Another problem is that carbapenemase producers,
specially K. pneumoniae and A. baumannii, are efﬁcient
cavengers of additional resistance mechanisms and, as a
onsequence, are constantly changing. In this sense, they
re a ‘‘moving target’’ and contemporary understandings
ay have reduced relevance to the therapeutic, diagnostic,
nd infection control challenges of the future. The current
eeds are for effective therapies, effective infection control
ased on better detection, education of health care profes-
ionals, and for research to provide better understandings
f the biology of these pathogens.
oi:10.1016/j.ijid.2010.02.1883
1.003
ontrolling the Spread of Carbapenemase-Producing Bac-
eria
. Schwaber
National Center for Infection Control, Tel Aviv, Israel
Background: During 2006, Israeli hospitals faced a
lonal outbreak of carbapenem-resistant Klebsiella pneu-
oniae, producing the serine carbapenemase KPC-3.
ocally-implemented infection control measures in affected
ospitals failed to contain spread. A nationwide intervention
as launched to contain the outbreak and introduce a strat-
gy to control future dissemination of antibiotic-resistant
acteria in hospitals.
Methods: In March 2007, the Ministry of Health issued
uidelines mandating physical separation of hospitalized
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arriers of carbapenem-resistant Enterobacteriaceae (CRE)
nd dedicated stafﬁng, and appointed a professional task
orce charged with containing spread of the epidemic strain.
he task force paid site visits at acute care hospitals, eval-
ated infection control policies and laboratory methods,
upervised adherence to the guidelines via daily census
eports on carriers and their conditions of isolation, provided
egular feedback on performance to hospital directors, and
ntervened additionally when necessary. During 2008, the
ntervention was extended to long-term care facilities, and
n June 2008 national guidelines for active surveillance were
ssued. The primary outcome measure was the incidence
f clinically diagnosed nosocomial CRE cases in acute care
ospitals.
Results: By March 2007, over 1200 patients were affected
n acute care hospitals. Prior to the intervention, the
onthly incidence of noscomial CRE climbed steadily, peak-
ng at over 180 cases. Crude 30-day mortality was > 30%.
ith the intervention, the continuous rise in incidence of
RE acquisition was halted, and at the end of the 14-month
nitial intervention period the number of new monthly cases
as 46. Following the introduction of active surveillance
uidelines, monthly incidence fell further, reaching a low
f 24 as of October 2009. A direct correlation was observed
etween compliance with isolation guidelines and success in
ontainment of in-hospital CRE transmission.
Conclusions: A centrally-coordinated public health inter-
ention has succeeded in containing a nationwide outbreak
f CRE in Israeli hospitals after local measures failed.
he intervention demonstrates the importance of strategic
lanning and national oversight in combating antimicrobial
esistance.
oi:10.1016/j.ijid.2010.02.1884
1.004
reatment Options for Carbapenenam Resistant Infections
. Daikos
University of Athens, Athens, Greece
Carbapenemase producing Gram-negative bacteria
CPGN) become increasingly prevalent and cause serious
nfections resulting in high fatality. These organisms are
esistant, not only to almost all available !-lactam antibi-
tics but also to other classes of agents, leaving tigecycline
nd colistin as the only therapeutic options. None of
hese agents, however, is ideal; tigecycline produces low
lood levels and colistin has questionable performance in
erious infections owing to poor pharmacokinetics. More
orryingly, resistance to both of these compounds has been
eveloped. The newer !-lactamase inhibitors, NXL 104 and
AL 30376, show promises for infections caused by CPGN. A
roportion of carbapenemase-producing Enterobacteriacae
as MICs of carbapenems within the susceptible range
aising the critical question of whether carbapenems might
e effective in the treatment of infections caused by such
rganisms.Anecdotal reports claim microbiological and clinical
esponse in patients infected with MBLpositive carbapenem-
usceptible organisms after treatment with a carbapenem.
n a prospective study of 67 patients with bloodstream infec-
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ions caused by VIM-producing K. pneumoniae, the lowest
ortality was observed in the group of patients who had
eceived combination therapy with two active drugs, one
f which was a carbapenem and the other either colistin or
n active aminoglycoside, whereas therapy with one active
rug resulted in a mortality similar to that observed in
atients who had received therapy with no active drug.
ased on this experience, it remains doubtful whether
onotherapy with a carbapenem would be effective in the
reatment of such infections. On the other hand, carbapen-
ms in combination with another active agent may provide
ome therapeutic beneﬁt against MBL-positive carbapenem-
usceptible Enterobacteriaceae. In this respect, the issue of
ither reporting such isolates as fully resistant to carbapen-
ms or consider the respective MICs at face value should
emain open. In conclusion, information about how to treat
nfections caused by CPGN is surprisingly scarce.
oi:10.1016/j.ijid.2010.02.1885
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2.001
alaria Eradication
.V. Plowe
University of Maryland School of Medicine, Baltimore21201,
D, USA
A global campaign to eradicate malaria in the middle
f the last century relied chieﬂy on two powerful tools,
nsecticide spraying of mosquitoes to interrupt transmission
nd chloroquine treatment to reduce the human reservoir
f infection. While this effort, led by the World Health
rganization, did succeed in eliminating malaria from some
reas on the edges of the malaria map, it was aban-
oned as a failure after little more than a decade. The
mergence of insecticideresistant Anopheles mosquitoes
nd drug-resistant Plasmodium falciparum parasites, failure
o understand and adapt to local differences in mosquito
cology and malaria epidemiology, and donor fatigue, all
ontributed to the demise of the campaign, which never
ncluded Africa, the region with by far the greatest malaria
urden, then and now. In the ensuing decades, the focus
hifted from eradication to control, and worldwide malaria
eaths increased in the face of chloroquine resistant falci-
arum malaria and weak health care systems.
The development and deployment of two new tools,
ong-lasting insecticide-treated nets and artemisinin-based
ombination drug treatments, have led to dramatic reduc-
ions in malaria in several countries, including some
n Africa. Malaria has even been completely eliminated
ecently from some endemic areas with low levels of trans-
ission and relatively good health infrastructure. These
uccess stories have generated such optimism that Bill
nd Melinda Gates and other donors and, following their
ead, malariologists, are talking again about eradication. To
chieve a better outcome than the ﬁrst campaign, malaria
radicators in the 21st century will need to learn and apply
essons from both past and recent failures and successes.
f a renewed malaria eradication effort is started with the
ools in hand now, it will be essential to keep the pipeline
